Allergy Testing Methods: Skin Tests, Blood Tests, and Patch Tests

Allergy testing establishes which specific allergens trigger an immune response in a given individual, providing the diagnostic foundation for treatment planning. Three principal method categories — skin tests, blood tests, and patch tests — differ in mechanism, clinical setting, sensitivity, and the allergen classes they reliably detect. Understanding how each method works, what it measures, and where it fails helps clinicians select the appropriate approach and helps patients interpret results accurately. The allergy diagnosis process depends on matching the right test to the clinical question.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

Allergy testing encompasses a set of diagnostic procedures designed to identify immunologically mediated hypersensitivity reactions. The American Academy of Allergy, Asthma & Immunology (AAAAI) distinguishes between tests that detect IgE-mediated (Type I) reactions — the mechanism behind classic allergic rhinitis, food allergy, and anaphylaxis — and tests that detect T-cell-mediated (Type IV) reactions, which underlie allergic contact dermatitis.

The three established test categories operate on fundamentally different biological principles:

• Skin prick/puncture and intradermal tests detect IgE-mediated sensitization through a localized wheal-and-flare response.
• Specific IgE blood tests (formerly called RAST, now conducted with fluorescent enzyme immunoassays such as ImmunoCAP) quantify circulating allergen-specific IgE antibodies.
• Patch tests detect delayed (Type IV) contact sensitization by occluding allergens against intact skin for 48 to 96 hours.

The regulatory context for allergy testing in the United States is governed primarily by the Food and Drug Administration (FDA), which regulates allergenic extracts used in skin testing under 21 CFR Part 680, and the Centers for Medicare & Medicaid Services (CMS), which classifies laboratory IgE testing under Clinical Laboratory Improvement Amendments (CLIA) standards.

Patch test materials marketed in the US, including the Thin-layer Rapid Use Epicutaneous (TRUE) Test — the only FDA-approved standardized patch test panel — are regulated as medical devices under 21 CFR Part 880. The TRUE Test panel contains 36 allergens and allergen mixes, covering the most prevalent contact sensitizers identified in the North American Contact Dermatitis Group (NACDG) surveillance network.

Core mechanics or structure

Skin prick test

The skin prick (or puncture) test introduces a minute quantity of allergen extract through the epidermis using a lancet, bifurcated needle, or multi-test device. A positive reaction produces a wheal — a raised, pale, circumscribed area surrounded by erythema (flare) — within 15 to 20 minutes. The wheal diameter is measured at its widest point; a wheal ≥3 mm greater than the negative saline control is the widely applied threshold for a positive result, as defined in AAAAI/American College of Allergy, Asthma and Immunology (ACAAI) practice parameters.

Intradermal testing injects 0.02–0.05 mL of allergen extract directly into the dermis, producing an initial bleb. This method is approximately 100-fold more sensitive than the skin prick test and is used when prick tests are negative but clinical suspicion remains high, particularly for Hymenoptera venom allergy and drug allergy evaluation.

Specific IgE blood test

Serum-based IgE testing quantifies allergen-specific IgE in kilounits per liter (kUA/L). The ImmunoCAP system, produced by Thermo Fisher Scientific and validated against multiple published reference datasets, reports results on a scale from Class 0 (<0.10 kUA/L) to Class 6 (≥100 kUA/L). The CAP system has a functional sensitivity of 0.10 kUA/L. Results do not directly predict reaction severity; a high IgE level indicates sensitization, not necessarily clinical allergy.

Patch test

Patch testing applies allergen-impregnated chambers or tape strips to the upper back under occlusion. Readings occur at 48 hours (when patches are removed) and again at 96 hours, because some contact allergens produce reactions that peak or first appear on the delayed reading. The International Contact Dermatitis Research Group (ICDRG) grading scale scores reactions from negative (−) through doubtful (+?) to extreme positive (+++), based on erythema, induration, vesicle formation, and bullae.

Causal relationships or drivers

The biological driver of skin prick and blood IgE tests is sensitization: prior allergen exposure that triggered IgE production by plasma cells. On re-exposure, IgE bound to mast cells and basophils cross-links, releasing histamine, tryptase, and other mediators. The skin prick test exploits this by placing allergen directly over mast cell–rich dermis.

Patch testing operates through a different pathway. CD4+ T helper cells (specifically Th1 cells) that were previously primed to a contact allergen release cytokines upon re-exposure, producing the delayed-type hypersensitivity reaction. No IgE is involved; consequently, antihistamines do not suppress patch test results, whereas they do suppress wheal-and-flare reactions in skin prick testing.

The allergy causes and triggers that predict a positive test result include the degree of prior exposure, individual genetic predisposition (particularly HLA haplotype variants in contact allergy), and the route of sensitization — transcutaneous sensitization through a disrupted skin barrier is a recognized driver of food and contact allergy as described in the epithelial barrier hypothesis published in the Journal of Allergy and Clinical Immunology.

Classification boundaries

Not all test types are interchangeable. Clinical guidelines from AAAAI and ACAAI establish the following boundaries:

Appropriate use of skin prick testing: Aeroallergens (pollens, dust mites, mold spores, animal dander), food allergens, insect venom, and some drug allergens where validated extracts exist.

Appropriate use of specific IgE blood testing: Same allergen classes as skin prick testing, with particular utility when skin testing is contraindicated — e.g., severe eczema covering the test site, patient is taking antihistamines that cannot be withheld, or risk of anaphylaxis during skin testing is elevated.

Appropriate use of patch testing: Evaluation of allergic contact dermatitis. Patch testing is not appropriate for IgE-mediated food allergy or inhalant allergy, and it does not identify irritant contact dermatitis (a non-immunologic reaction requiring separate clinical evaluation).

Not validated for clinical use: Applied kinesiology, cytotoxic testing (Bryan's test), provocation-neutralization testing, and electrodermal testing are not accepted by AAAAI, ACAAI, or the Joint Task Force on Practice Parameters as valid diagnostic methods for allergy.

Tradeoffs and tensions

Sensitivity versus specificity represents the central tension in allergy testing. Intradermal tests are more sensitive than skin prick tests but less specific — they produce more false-positive results. Specific IgE blood tests have lower sensitivity than skin prick tests for aeroallergens (approximately 70–95% depending on the allergen and population studied, per AAAAI position statements), but they eliminate the risk of systemic reaction during testing.

The interpretation gap between sensitization and clinical allergy creates a second major tension. A patient may have measurable IgE to peanut but tolerate peanut consumption without symptoms; conversely, a patient with low IgE levels may react to minimal exposure. This is why the oral food challenge remains the diagnostic gold standard for food allergy confirmation — it directly tests clinical reactivity rather than surrogate biomarkers.

Patch testing carries its own tradeoffs: the requirement for 2 clinical visits over 96 hours limits compliance, allergen concentration must be calibrated to avoid active sensitization during the test itself (a phenomenon called patch test sensitization), and interpretation requires trained dermatology or allergy specialists because false positives from irritant reactions are common with improperly prepared test materials.

The breadth of the allergen panel tested introduces a cost-versus-information tension. Broad multiplex IgE component testing (molecular allergology) using panels such as ISAC (Immuno Solid-phase Allergen Chip) can test IgE against more than 100 allergen components simultaneously, but AAAAI and ACAAI note that untargeted broad testing increases the risk of detecting clinically irrelevant sensitizations.

Common misconceptions

Misconception: A positive allergy test means the patient is allergic.
Correction: A positive skin prick or IgE test indicates sensitization. Clinical allergy requires both a positive test and a history of symptoms upon exposure to the specific allergen. AAAAI practice parameters explicitly state that test results must always be interpreted in the context of the clinical history.

Misconception: Blood tests are more accurate than skin tests.
Correction: Accuracy depends on the allergen and the clinical question. For many aeroallergens, skin prick testing performed with standardized extracts by trained personnel has higher sensitivity than serum IgE testing. Neither is universally superior.

Misconception: Patch tests diagnose food allergy.
Correction: Patch testing detects Type IV contact hypersensitivity. Atopy patch tests (applying food antigens under occlusion) are an area of research but are not FDA-approved, not standardized, and explicitly excluded from routine food allergy diagnosis by AAAAI and ACAAI joint guidelines.

Misconception: Stopping antihistamines for 3 days is sufficient before skin testing.
Correction: Different antihistamines suppress wheal-and-flare reactions for variable durations. First-generation antihistamines such as diphenhydramine require a 3-day washout; second-generation antihistamines such as cetirizine and loratadine may require 3–7 days; hydroxyzine may require up to 10 days. Tricyclic antidepressants and some antipsychotics also suppress skin test reactions and require longer washout periods, per ACAAI clinical guidance.

Misconception: Home allergy test kits provide equivalent results.
Correction: Direct-to-consumer IgE testing kits are not equivalent to clinically ordered and interpreted specific IgE panels. The FDA has issued guidance indicating that some home tests report results without established clinical decision thresholds, and results without clinical context have a high potential for misinterpretation.

Checklist or steps (non-advisory)

The following sequence describes the standard procedural elements of a clinical allergy skin prick test session, as outlined in ACAAI and AAAAI practice parameters. This is a process description, not clinical guidance.

1. Medical history review — Clinician documents symptom history, prior reaction history, current medications (particularly antihistamines, beta-blockers, and ACE inhibitors), and contraindications to skin testing.
2. Medication washout confirmation — Relevant medications are confirmed to have been withheld for appropriate intervals before testing.
3. Test site selection and preparation — Volar forearm or upper back is cleaned with alcohol; site is marked to identify each allergen position.
4. Control application — Histamine positive control (typically 1 mg/mL or 10 mg/mL histamine base) and saline negative control are applied first to validate reactivity and confirm dermographism status.
5. Allergen extract application — Single drops of standardized allergen extract are placed at marked sites, typically spaced ≥2 cm apart.
6. Skin puncture — Lancet or multi-test device punctures through each extract drop; devices are applied perpendicularly with uniform pressure.
7. Waiting period — Patient remains stationary for 15–20 minutes; site is not wiped.
8. Wheal measurement — Orthogonal diameters (longest and perpendicular) of each wheal are measured in millimeters; mean wheal diameter is recorded.
9. Result interpretation — Wheals are compared against positive and negative controls; results ≥3 mm greater than the negative control are recorded as positive.
10. Post-test observation — Patient is observed for systemic reactions; epinephrine must be immediately available in the testing setting per AAAAI standards.

For a broader overview of the allergen landscape relevant to testing decisions, the home page of this resource provides navigational context across allergy types and treatment approaches.

Reference table or matrix

Allergy Testing Method Comparison Matrix

References

• American Academy of Allergy, Asthma & Immunology (AAAAI) — Practice parameters, position statements on allergy testing methods, and definition of sensitization versus clinical allergy.
• American College of Allergy, Asthma and Immunology (ACAAI) — Clinical guidance on skin test technique, antihistamine washout periods, and specific IgE testing indications.
• U.S. Food and Drug Administration (FDA) — 21 CFR Part 680 — Federal regulation of allergenic products used in diagnostic skin testing.
• U.S. Food and Drug Administration (FDA) — 21 CFR Part 880 — Federal regulation of general hospital and personal use devices, including patch test panels.
• Centers for Medicare & Medicaid Services (CMS) — Clinical Laboratory Improvement Amendments (CLIA) — Standards governing laboratory IgE testing.
• North American Contact Dermatitis Group (NACDG) — Surveillance data on contact allergen prevalence informing patch test panel composition.
• International Contact Dermatitis Research Group (ICDRG) — Grading scale for patch test reaction interpretation.
• Joint Task Force on Practice Parameters (JTFPP) — Allergy testing practice parameters published jointly by AAAAI and ACAAI.

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)